Evidence map›Paper›PMID 42303867›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Improved early response assessment of chemoimmunotherapy efficacy by

Xiuling Shen, Zhengjie Wang, Zhu Xia, Yupin Yi, Wenbo Li, Rui Zhang, Xiaoyang Zhang, Biao Xia, Weibin Jiang, Chunxiao Zheng and 7 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiuling Shen *Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zhengjie Wang *Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zhu Xia *Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yupin YiDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Wenbo LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Rui ZhangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xiaoyang ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Biao XiaDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Weibin JiangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Chunxiao ZhengDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Qin WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Jia LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Jianqiu LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Lu XuDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zhaofei LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, Beijing, 100142, China. liuzf@bjmu.edu.cn.
Nan LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, Beijing, 100142, China. rainbow6283@sina.com.
Hua PangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. phua1973@163.com.ORCID 0000-0001-6601-3208

Funding

China Postdoctoral Science Foundation 2025MD774166National Natural Science Foundation of China 82325028, 92459302, and U25A20139Natural Science Foundation of Beijing Municipality L252055, Z220011, and Z220014Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission CSTB2025NSCQ-GPX1147Postdoctoral Fellowship Program of CPSF GZC20251447
6 · The paper itself

Abstract

backgroundChemoimmunotherapy outperforms immunotherapy alone in advanced non-small cell lung cancer (NSCLC). However, current anatomical imaging and programmed death-ligand 1 (PD-L1) assessments are insufficient for early response prediction and do not directly capture treatment-induced immune effector function. Whether

methodsIn this prospective study, 60 patients with advanced NSCLC receiving BAI-based (n = 28) or intravenous (n = 32) chemoimmunotherapy underwent

resultsBAI-based chemoimmunotherapy showed higher

conclusions

trial registrationChiCTR2500105792, the registration date is 2025-07-10, https://www.chictr.org.cn/showproj.html?proj=275165 .

Indexed as

Bronchial ArteriesCarcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsPositron Emission Tomography Computed TomographyAdministration, IntravenousAgedFemaleGallium RadioisotopesHumansMaleMiddle AgedTreatment OutcomeGallium RadioisotopesBronchial arterial infusionEarly response assessmentGranzyme BImmunotherapyNon-small cell lung cancer

Identifiers

PMID42303867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.